Romidepsin
CAS No. 128517-07-7
Romidepsin ( FK228, Depsipeptide )
Catalog No. M11164 CAS No. 128517-07-7
Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM, respectively.
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 139 | In Stock |
|
5MG | 224 | In Stock |
|
10MG | 404 | In Stock |
|
25MG | 583 | In Stock |
|
50MG | 830 | In Stock |
|
100MG | 1125 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRomidepsin
-
NoteResearch use only, not for human use.
-
Brief DescriptionRomidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM, respectively.
-
DescriptionRomidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM, respectively.
-
SynonymsFK228, Depsipeptide
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC1; HDAC2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number128517-07-7
-
Formula Weight540.70
-
Molecular FormulaC24H36N4O6S2
-
Purity>98%(HPLC)
-
SolubilityDMSO: 10 mg/mL (18.49 mM)
-
SMILESO=C([C@H](C(C)C)NC(/C(N1)=C/C)=O)O[C@](CC(N[C@H](C(C)C)C(N2)=O)=O)([H])/C=C/CCSSC[C@]2([H])C1=O
-
Chemical Name(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(1methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16ene-3,6,9,19,22-pentone
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Furumai R, et al. Y Res, 2002, 62(17), 4916-492
molnova catalog
related products
-
AES-135
AES-135 (AES135) is a novel HDAC inhibitor that biochemically inhibits HDACs 3, 6, 8 and 11 with IC50 values of 190-1100 nM.
-
Merck60
Merck60 (BRD 6929, Compound-60)is a potent, selective and brain-penetrant inhibitor of HDAC1 and HDAC2 with IC50 of 1 nM and 8 nM respectively.
-
Remodelin Fluor
Remodelin Fluor is a small molecule analog of Remodelin, demonstrates in vivo activitiy against NAT10.